Patent classifications
A61K31/131
TOPICAL COMPOSITION FOR TREATING SKIN WOUNDS
A composition for treating skin wounds of an individual is disclosed. The composition is an extract that contains Zinc Gluconate, Lysine, Taurine, Potassium Gluconate, Carboxy Methyl Cellulose, Glycerin, Allantoin, water, Hydrogen chloride (HCl), Lidocaine, Niacin, Valine, L-Isoleucine, Proline, L-Arginine, Threonine, Glutamine, Histidine, Serine, Asparagine, Tyrosine, Cysteine, and pentapeptide for example, Enkephalin. The composition could be applied to the affected skin for effectively treating skin wounds, reducing expression lines, and relaxing muscle contractions, thereby reducing skin wrinkles, and smoothening skin. The composition is provided in at least any one or more forms include a gel, a spray, liquid, lotion, and a cream. The composition maintains a pH balance ranges from about 6.5 to 7.5.
TOPICAL COMPOSITION FOR TREATING SKIN WOUNDS
A composition for treating skin wounds of an individual is disclosed. The composition is an extract that contains Zinc Gluconate, Lysine, Taurine, Potassium Gluconate, Carboxy Methyl Cellulose, Glycerin, Allantoin, water, Hydrogen chloride (HCl), Lidocaine, Niacin, Valine, L-Isoleucine, Proline, L-Arginine, Threonine, Glutamine, Histidine, Serine, Asparagine, Tyrosine, Cysteine, and pentapeptide for example, Enkephalin. The composition could be applied to the affected skin for effectively treating skin wounds, reducing expression lines, and relaxing muscle contractions, thereby reducing skin wrinkles, and smoothening skin. The composition is provided in at least any one or more forms include a gel, a spray, liquid, lotion, and a cream. The composition maintains a pH balance ranges from about 6.5 to 7.5.
ENHANCER OF PHOTODYNAMIC EFFECT IN ALA-PDT OR ALA-PDD
The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.
ENHANCER OF PHOTODYNAMIC EFFECT IN ALA-PDT OR ALA-PDD
The object of the present invention is to potentiate the photodynamic effect in ALA-PDT and ALA-PDD. The present invention provides a pharmaceutical related to a combination of ALAs and a dynamin inhibitor.
USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION
The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of Chemical Formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating or treating cognitive disorder or for improving enhancing cognitive function.
USE OF IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE COMPOUNDS FOR PREVENTION, ALLEVIATION, OR TREATMENT OF COGNITIVE DISORDERS, OR FOR IMPROVING COGNITIVE FUNCTION
The present invention relates to a use of imidazopyrimidine or imidazotriazine compounds of Chemical Formula 1, or pharmaceutically acceptable salts, solvates, or hydrates thereof, for preventing, alleviating or treating cognitive disorder or for improving enhancing cognitive function.
2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME
The invention includes 2-β-naphthyl-acetic acid derivatives, which are selective AKR1C3 inhibitors. In certain embodiments, the compounds of the invention are R-naproxen analogs. The invention further includes methods of treating cancer, such as prostate cancer and/or castration-resistant prostate cancer, using at least one compound of the invention.
TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
##STR00001##
TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS
Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
##STR00001##
USE OF A COMBINATION OF NITROGEN AND HYDROGEN BASED COMPOUNDS WITH AN AMINO ACID AND A STIMULANT
This invention relates a method of orally administering a liquid consisting of a combination of nitrogen based compounds consisting of nitrogen, nitric oxide or nitrous oxide with amino acids and/or amino acid peptides salts and esters and stimulants and stimulant salts to increase athletic performance, anti-aging focus, and energy output, and a method of administering a combination of combining hydrogen compounds, consisting of hydrogen gases and/or ions including but not limited to H2 and H+ signaling molecules with both D and L forms of amino acids and/or amino acid peptides salts and esters, and stimulants and stimulant salts for providing increased athletic performance via hydration, for increased energy output, and for the reduction of free radical damage.